Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Karyopharm Therapeutics (KPTI) Interest Expenses (2019 - 2025)

Karyopharm Therapeutics' Interest Expenses history spans 9 years, with the latest figure at $12.6 million for Q4 2025.

  • For Q4 2025, Interest Expenses rose 12.63% year-over-year to $12.6 million; the TTM value through Dec 2025 reached $45.8 million, up 22.52%, while the annual FY2025 figure was $45.8 million, 22.52% up from the prior year.
  • Interest Expenses reached $12.6 million in Q4 2025 per KPTI's latest filing, up from $11.0 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $12.6 million in Q4 2025 to a low of $5.0 million in Q2 2021.
  • Average Interest Expenses over 5 years is $7.9 million, with a median of $6.5 million recorded in 2022.
  • Peak YoY movement for Interest Expenses: decreased 26.0% in 2021, then soared 87.47% in 2024.
  • A 5-year view of Interest Expenses shows it stood at $7.9 million in 2021, then dropped by 25.88% to $5.9 million in 2022, then grew by 5.49% to $6.2 million in 2023, then soared by 80.48% to $11.2 million in 2024, then increased by 12.63% to $12.6 million in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Interest Expenses are $12.6 million (Q4 2025), $11.0 million (Q3 2025), and $11.2 million (Q2 2025).